Board ReviewOB/GYNStudy guide

Cervical Cancer for the OB-GYN Shelf: 2026 Screening Rules, Abnormal Results and FIGO Staging

Who gets cytology, primary HPV or self-collection in 2026, what to do with an abnormal result, HPV vaccine timing and the FIGO 2018 stages for the OB-GYN shelf.

Step 2 CK outlineRenal & Urinary System & Reproductive SystemsHealth Maintenance/Disease PreventionLaboratory/Diagnostic StudiesMixed ManagementObstetrics & Gynecology

A laboratory microscope with a stained slide on the stage in a pathology lab
AI-generated image
Contents
  1. The screening timeline
  2. HPV vaccination
  3. The approach to an abnormal result
  4. FIGO 2018 staging
  5. Clue in the stem, next best step
  6. Where students lose points
  7. Practice question
  8. 60-second recall
  9. Sources

Cervical cancer on the OB-GYN shelf is mostly a screening topic. A question gives an age, a test result and sometimes a pregnancy, and asks what happens next: routine screening, a repeat test, colposcopy or treatment. Staging appears less often, usually as one finding (hydronephrosis, parametrial spread) that sets the stage.

The screening timeline

For average-risk patients with a cervix, following ACOG guidance updated in 2026.

  1. Under 21: no screeningRegardless of sexual activity. HPV infection at this age usually clears.
  2. 21 to 29: cytology every 3 yearsHPV testing is not used for routine screening under 30 in this schedule. The American Cancer Society instead starts at 25 with primary HPV testing every 5 years.
  3. 30 to 65: primary high-risk HPV testing every 5 years, preferredClinician-collected samples are preferred. Self-collected vaginal HPV testing with an FDA-approved device is an acceptable option; after a negative self-collected test, ACS and the Enduring Consensus guidelines repeat in 3 years. Cotesting every 5 years or cytology every 3 years remains acceptable.
  4. Over 65: stop after adequate negative screeningACS now asks for negative HPV-based tests at 60 and 65 before exit. Patients with a history of CIN2 or worse continue for at least 25 years after treatment.
  5. After hysterectomy: usually stopIf the cervix was removed for a benign reason and there is no history of CIN2 or worse, screening ends.

Sources differ on the details: the USPSTF's December 2024 draft also prefers primary HPV testing from 30 to 65 and includes self-collection, but on a 5-year interval. Exams follow the core schedule above, which all groups share.

HPV vaccination

  • Routine at 11 to 12 years; it can start at 9.
  • Catch-up through 26 years for anyone not adequately vaccinated.
  • 27 to 45 years: shared clinical decision-making, not routine.
  • Two doses (0 and 6 to 12 months) if started before the 15th birthday; three doses if started at 15 or later or if immunocompromised.
  • Vaccinated patients follow the same screening schedule.

The approach to an abnormal result

The 2019 ASCCP guidelines manage by risk: the test result plus prior history estimate the immediate risk of CIN3 or worse, and that risk sets the next step.

  1. HPV 16 or 18 positiveColposcopy, whatever the cytology shows.
  2. Other high-risk HPV types positiveReflex cytology on the same sample decides: normal cytology usually means repeat HPV testing in 1 year; ASC-US or worse means colposcopy.
  3. ASC-US with a negative HPV testRepeat HPV-based testing in 3 years.
  4. LSIL, or ASC-US that is HPV positiveColposcopy for most patients 25 and older.
  5. HSILColposcopy, or expedited excision (LEEP) without colposcopy in nonpregnant patients 25 or older when the risk is high, such as HSIL with HPV 16.
  6. Atypical glandular cellsColposcopy with endocervical sampling, plus endometrial sampling if 35 or older or at risk for endometrial cancer.
  7. CIN2 or CIN3 on biopsyExcision, usually LEEP. Observation is an option for CIN2 in patients concerned about future pregnancy.

Patients 21 to 24 are managed more conservatively: ASC-US or LSIL means repeat cytology in 1 year rather than colposcopy. In pregnancy, colposcopy is safe, endocervical curettage is avoided, and treatment of CIN waits until after delivery unless invasive cancer is suspected.

FIGO 2018 staging

StageExtentThe detail that gets tested
IA1Microscopic, stromal invasion 3 mm or lessLateral width no longer counts
IA2Stromal invasion more than 3 mm and up to 5 mmStill microscopic
IB1 to IB3Confined to the cervix, split by size: 2 cm or less, 2 to 4 cm, more than 4 cmIB3 is treated as locally advanced
IIAUpper two-thirds of the vagina, no parametrial invasion
IIBParametrial invasion, not to the pelvic wall
IIIA to IIIBLower third of the vagina, or pelvic wall, or hydronephrosis or a nonfunctioning kidneyHydronephrosis means at least IIIB
IIIC1 and IIIC2Pelvic or para-aortic lymph node metastasisImaging or pathology can assign it
IVA and IVBBladder or rectal mucosa, or distant metastasis

In broad terms, early disease is treated surgically (conization or simple hysterectomy for IA1, radical hysterectomy with nodal assessment for small IB tumors), and locally advanced disease (IB3 and higher) with concurrent cisplatin-based chemoradiation and brachytherapy.

Clue in the stem, next best step

Clue in the stemWhat it points toNext best step
19-year-old, sexually active, asks for a Pap testBelow screening ageNo cervical screening; offer HPV vaccine and STI testing
26-year-old, normal cytology 3 years agoDue for routine screeningCytology (or primary HPV at 25 or older under ACS)
35-year-old, primary HPV positive for HPV 16High immediate riskColposcopy
40-year-old, HPV positive (not 16 or 18), reflex cytology normalLower riskRepeat HPV testing in 1 year
23-year-old with LSILYoung patient, likely to clearRepeat cytology in 1 year
Pregnant at 14 weeks with HSILAbnormal screen in pregnancyColposcopy without endocervical curettage; defer treatment unless cancer suspected
Cervical mass and new bilateral hydronephrosisPelvic wall or ureteral involvementStage at least IIIB; chemoradiation

Where students lose points

  • Screening a 19-year-old because she is sexually active, or adding HPV testing at 21 to 24.
  • Repeating cytology for an HPV 16 positive result. It goes to colposcopy.
  • Sending a 22-year-old with LSIL to colposcopy.
  • Performing endocervical curettage, or treating CIN, during pregnancy.
  • Stopping screening at 65 without confirming adequate prior negative results.
  • Using the old 7 mm width criterion for stage IA. FIGO 2018 removed it.
  • Telling a vaccinated patient she can skip screening.

Practice question

A 34-year-old woman, gravida 2, para 2, comes for a routine visit. Her last screening was 5 years ago with a negative primary HPV test. She has no symptoms. She uses a levonorgestrel IUD and has had one sexual partner for 8 years. Pelvic examination is normal. A clinician-collected primary HPV test is positive for HPV 16.

Which of the following is the most appropriate next step in management?

  1. Repeat HPV testing in 1 year
  2. Repeat HPV testing in 3 years
  3. Colposcopy
  4. Loop electrosurgical excision procedure
  5. Routine screening in 5 years
Show the answer

Answer: C. Under the 2019 ASCCP risk-based guidelines, a positive test for HPV 16 or 18 carries enough immediate risk of CIN3 or worse to require colposcopy, regardless of the cytology result.

Why the others are wrong. A and B: surveillance intervals apply to lower-risk results, such as HPV positivity for other types with normal cytology. D: expedited excision without colposcopy is reserved for very high-risk results, such as HSIL with HPV 16. E: a positive high-risk HPV result ends routine screening until it is worked up.

60-second recall

Say each answer out loud before you reveal it, then mark yourself. Retrieval, not rereading, is what makes it stick.

  1. 121 to 29
    Cytology every 3 years.
    Did you get it?
  2. 230 to 65
    Primary HPV every 5 years preferred; self-collection is an option (repeat in 3 years after a negative self-collected test under ACS).
    Did you get it?
  3. 3HPV 16 or 18 positive
    Colposcopy.
    Did you get it?
  4. 4Ages 21 to 24 with ASC-US or LSIL
    Repeat cytology in 1 year.
    Did you get it?
  5. 5HPV vaccine
    Routine at 11 to 12, catch-up to 26, two doses if started before 15.
    Did you get it?
  6. 6Hydronephrosis
    Stage IIIB at least.
    Did you get it?

Next: browse every Board Review post, review endometrial cancer for the OB-GYN shelf, or see MedRise for students.

Sources

  1. Healio. ACOG updates cervical cancer screening guidance to include self-collection option. April 24, 2026
  2. American College of Obstetricians and Gynecologists. Cervical cancer screening guidance, 2026 (Guideline Central summary)
  3. Perkins RB, et al. Self-collected vaginal specimens for HPV testing and guidance on screening exit: an update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin, 2026 (PubMed 41342729)
  4. US Preventive Services Task Force. Cervical cancer: screening (including the December 2024 draft update)
  5. Perkins RB, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis, 2020 (PubMed 32243307)
  6. Meites E, et al. Human papillomavirus vaccination for adults: updated recommendations of the ACIP. MMWR, 2019 (PubMed 31415491)
  7. Bhatla N, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet, 2019 (PubMed 30656645)

MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.

Learned something the hard way on a shelf or on the wards?

Write it up for MedRise Perspectives: 600 to 1,200 words, published under your name, with a decision usually within one day.

Book a free strategy call

Ten minutes to look at your exam date, your scores and what is getting in the way.